slider

Disease Oriented Research Teams - DOTs

Michael Deininger

Michael Deininger, MD, PhD

HCI Senior Director of Transdisciplinary Research
M. M. Wintrobe, MD Presidential Endowed Chair in Internal Medicine

Chief, Division of Hematology and
Hematological Malignancies
University of Utah

Cancer Center Bio

HCI leadership has made a strategic commitment to develop disease oriented research teams (DOTs) as a mechanism to enhance cancer focus, transdisciplinary integration, and collaboration. The ultimate objective of the DOT program is to maximize the impact of HCI discoveries on cancer patients. As such the DOTs are a strategic initiative designed to enhance transdisciplinary coordination and collaboration at HCI. The DOT initiative is supported thanks to generosity of donors to the Huntsman Cancer Foundation. Funds to DOTs are awarded annually via a competitive, peer-reviewed RFA process.

Michael Deininger, MD, PhD, serves as Senior Director of Transdisciplinary Research at Huntsman Cancer Institute and oversees the DOTs.

HCI has invested in 10 Disease Oriented Research Teams. DOTs specialize in adult and pediatric cancer research in the following areas:

  • Colon Cancer
  • Genitourinary Malignancies
  • Hematologic Malignancies
  • Hepatobiliary Cancer
  • Melanoma
  • Neuro-Oncology
  • Pancreatic Cancer
  • Sarcoma
  • Upper Aero Digestive Tract
  • Women’s Cancers
ExpansionResearch 2 Research 3 Research 4 Research 5